Aggregates disrupt neuronal functions and propagate in a prion-like manner, with SNCA mutations exacerbating α-Syn aggregation and disease severity. Alpha-synuclein levels in skin, serum, cerebrospinal fluid, and plasma distinguish PD patients from healthy patients, demonstrating biomarker potential for diagnosis and therapeutic strategies. The gene discussed is SNCA; the disease is Parkinson disease.